» Articles » PMID: 29062018

IFN-γ and TNF-α Synergism May Provide a Link Between Psoriasis and Inflammatory Atherogenesis

Abstract

Chronic inflammation is a critical component of atherogenesis, however, reliable human translational models aimed at characterizing these mechanisms are lacking. Psoriasis, a chronic inflammatory skin disease associated with increased susceptibility to atherosclerosis, provides a clinical human model that can be utilized to investigate the links between chronic inflammation and atherosclerosis development. We sought to investigate key biological processes in psoriasis skin and human vascular tissue to identify biological components that may promote atherosclerosis in chronic inflammatory conditions. Using a bioinformatics approach of human skin and vascular tissue, we determined IFN-γ and TNF-α are the dominant pro-inflammatory signals linking atherosclerosis and psoriasis. We then stimulated primary aortic endothelial cells and ex-vivo atherosclerotic tissue with IFN-γ and TNF-α and found they synergistically increased monocyte and T-cell chemoattractants, expression of adhesion molecules on the endothelial cell surface, and decreased endothelial barrier integrity in vitro, therefore increasing permeability. Our data provide strong evidence of synergism between IFN-γ and TNF- α in inflammatory atherogenesis and provide rationale for dual cytokine antagonism in future studies.

Citing Articles

Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients.

Mustata M, Neagoe C, Radulescu V, Dragne I, Cimpeanu R, Radu L Life (Basel). 2025; 15(2).

PMID: 40003621 PMC: 11856174. DOI: 10.3390/life15020212.


IFN-γ/TNF-α Synergism Induces Pro-Inflammatory Cytokine and Chemokine Production by In Vitro Canine Keratinocytes.

Jung K, Ku J, Kwon J, Won G, Yoon H, Oh S Vet Sci. 2025; 12(1.

PMID: 39852930 PMC: 11769522. DOI: 10.3390/vetsci12010055.


Cardiodermatology: the heart of the connection between the skin and cardiovascular disease.

Gelfand J, Song W, Langan S, Garshick M Nat Rev Cardiol. 2024; .

PMID: 39537837 DOI: 10.1038/s41569-024-01097-9.


Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine.

Mashima E, Saito-Sasaki N, Sawada Y Diagnostics (Basel). 2024; 14(20).

PMID: 39451595 PMC: 11506695. DOI: 10.3390/diagnostics14202272.


Molybdenum Nanoparticles Alleviate MC903-Induced Atopic Dermatitis-Like Symptoms in Mice by Modulating the ROS-Mediated NF-κB and Nrf2 /HO-1 Signaling Pathways.

Xiao Q, Guo J, Lu Y, Gao J, Jia C, Huang M Int J Nanomedicine. 2024; 19:8779-8796.

PMID: 39220192 PMC: 11365534. DOI: 10.2147/IJN.S472999.


References
1.
Harden J, Johnson-Huang L, Chamian M, Lee E, Pearce T, Leonardi C . Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol. 2014; 135(2):553-6. DOI: 10.1016/j.jaci.2014.05.046. View

2.
Agrawal S, Febbraio M, Podrez E, Cathcart M, Stark G, Chisolm G . Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation. 2007; 115(23):2939-47. DOI: 10.1161/CIRCULATIONAHA.107.696922. View

3.
Sikorski K, Chmielewski S, Olejnik A, Wesoly J, Heemann U, Baumann M . STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction. JAKSTAT. 2013; 1(4):241-9. PMC: 3670280. DOI: 10.4161/jkst.22469. View

4.
Gelfand J, Troxel A, Lewis J, Kurd S, Shin D, Wang X . The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007; 143(12):1493-9. DOI: 10.1001/archderm.143.12.1493. View

5.
Leonardi C, Kimball A, Papp K, Yeilding N, Guzzo C, Wang Y . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371(9625):1665-74. DOI: 10.1016/S0140-6736(08)60725-4. View